Dendrimers in Neurodegenerative Diseases

Neurodegenerative diseases (NDs), such as Parkinson’s Disease (PD), Alzheimer’s (AD), Multiple Sclerosis (MS) and amyotrophic lateral sclerosis (ALS), are characterized by progressive loss of structure or function neurons. Current therapies for NDs only symptomatic long-term ineffective. This challenge has promoted the development new against relevant targets in these pathologies. In this review, we will focus on most promising therapeutic approaches based dendrimers (DDs) specially designed treatment diagnosis NDs. DDs well-defined polymeric structures that provide a multifunctional platform developing different nanosystems myriad applications. have been proposed interesting drug delivery systems with ability to cross blood–brain barrier (BBB) increase bioavailability classical drugs brain, well genetic material, reducing synthesis specific targets, β-amyloid peptide. Moreover, shown be anti-amyloidogenic amyloid-β peptide (Aβ) Tau aggregation, powerful agents blocking α-synuclein (α-syn) fibrillation, exhibit anti-inflammatory properties, promote cellular uptake certain cell types, potential tools ND diagnosis. summary, emerged alternatives current since they may limit extent damage neuroprotection affected tissues.